Microbiome and intestinal permeability in dogs with EPI

Canine exocrine pancreatic insufficiency (EPI) occurs when the pancreas fails to produce enough digestive enzymes, leaving food poorly digested. Common signs include weight loss despite a good appetite, chronic diarrhoea, coprophagia, flatulence and a dull coat. The microbiome and intestinal permeability in dogs with exocrine pancreatic insufficiency are therefore closely related clinical questions, although each requires careful interpretation.

Dysbiosis may change after EPI develops, while inflammation and altered barrier function can further reshape the microbial community. Faecal analysis alone cannot measure intestinal permeability, and neither finding explains every clinical sign. Sound decisions come from combining dietary history, medication records, blood tests, faecal investigations and, when indicated, gastrointestinal biopsy.

What EPI changes inside the gut

Without adequate pancreatic enzymes, undigested nutrients reach the small intestine and create a favourable environment for abnormal microbial growth. Small intestinal bacterial overgrowth, excess fermentation and shifts in bacterial diversity are reported in affected dogs. These changes may reduce available nutrients and produce gas, discomfort and unstable faeces.

The intestinal barrier includes epithelial cells, tight junctions, mucus and immune defences. Inflammation can disrupt that barrier, increasing the movement of microbial products into the tissues and circulation. The popular term “leaky gut” captures this process, although veterinary permeability assessments remain less standardised than tests for EPI itself.

The relationship also runs in the other direction. Poor digestion alters the substrate available to intestinal microbes, and some bacterial products can promote inflammation. Current evidence supports an association between dysbiosis, inflammation and clinical severity, but it does not establish that every microbiome change directly causes increased permeability.

Interpreting dysbiosis without overreach

Faecal sequencing provides information about organisms leaving the body, not the full small-intestinal or mucosal community. Results are influenced by diarrhoea, transit time, diet, antibiotics, veterinary drugs and the time between collection and processing. A commercial laboratory report should therefore be interpreted alongside the clinical picture rather than treated as a stand-alone diagnosis.

Different sequencing methods also answer different questions. Marker-based surveys provide broad profiles, while shotgun sequencing can identify more bacterial and viral material but requires more complex interpretation. Neither method directly measures epithelial integrity. The feline IBD and lymphoma resource illustrates why careful clinicopathological correlation matters in chronic enteropathy, although feline findings cannot be transferred directly to dogs with EPI.

Repeated testing can help identify a persistent pattern, especially when samples are collected under similar conditions. A one-off result showing low diversity has limited significance. More useful questions include whether abnormal findings remain after obvious causes have been addressed and whether they coincide with weight loss, pain, vomiting or deteriorating faecal quality.

Building a practical diagnostic pathway

Serum trypsin-like immunoreactivity is central to confirming EPI, while vitamin B12, folate and nutritional status help characterise the consequences of malabsorption. Assessment of the small intestine may include faecal culture, imaging, endoscopy and histopathology. These investigations distinguish EPI alone from EPI complicated by bacterial overgrowth, inflammatory bowel disease, coeliac-type disease or neoplasia.

Enzyme replacement, appropriate feeding and correction of vitamin B12 deficiency remain the foundations of treatment. Antimicrobials may be indicated when bacterial overgrowth is demonstrated, but empirical use can suppress useful microbial populations and obscure the original pattern. Pancreatic enzymes should not be withheld simply because a microbiome test reports an abnormality.

A microbiome result also should not be used to dismiss other diagnoses. In a deteriorating dog, intestinal lymphoma, chronic inflammation or an obstructive lesion still need investigation. Clinical response, body weight, faecal score, appetite and serial laboratory results provide a more reliable framework for judging management than a single microbiome score.

Australian clinical realities

Australia has a strong companion-animal culture, and canine EPI is encountered in metropolitan Sydney and Melbourne as well as in regional and rural practices. German Shepherds remain a familiar breed in Australian homes and are among those commonly considered when pancreatic disease is suspected. Access to endoscopy varies, making clear referral pathways to specialist centres and university teaching hospitals important.

Hot conditions across much of Australia can complicate both health and sample logistics. Owners may report intermittent diarrhoea during warm weather, particularly after travel or abrupt dietary changes. Faecal samples should be collected promptly, labelled clearly and transported under laboratory instructions; heat exposure may reduce viability and alter community profiles before analysis.

Commercial pathology providers such as Gribbles and IDEXX Australia, together with university laboratories and veterinary referral services, support diagnosis and monitoring. Owners encounter feeds and supplements through veterinary clinics, pet retailers and online marketplaces, so Australian clinicians often need to clarify what a product claims, what evidence supports it and whether it complements or complicates prescribed care. Informal phrases such as “dodgy gut” or “a bit off” are useful conversation starters, but they do not define the underlying disease.

Connecting evidence with better decisions

The Hills ActivBiome educational programme brings together accessible material on microbiome science, with research partnerships involving Harvard T.H. Chan School of Public Health, Texas A&M University and the University of Vienna. The expert speaker perspectives provide a useful starting point for understanding how veterinary clinicians translate microbiome research into investigations of chronic gastrointestinal disease.

On-demand presentations, downloadable resources and participation certificates support continuing professional development for Australian veterinary teams. Their practical value lies in building a consistent process: define the clinical problem, confirm primary disease, assess complications and monitor objective change. That process is more defensible than prescribing a generic “gut health” intervention because a faecal profile appears abnormal.

For owners, results are most meaningful when paired with visible outcomes such as stable weight, improved faecal quality and comfortable behaviour. For clinicians, microbiome and permeability assessments remain complementary tools within a broader nutritional and diagnostic framework. Used that way, they can reveal important patterns in EPI without overstating what the evidence currently supports.